Table 1.
Association between clinicopathological factors and different SII groups.
| Parameters | n = 249 (%) | SII ≤ 547 | SII > 547 | X 2 | P value |
|---|---|---|---|---|---|
| Cases | n = 183 (%) | n = 66 (%) | |||
| Age (years) | 2.493 | 0.114 | |||
| ≤51 | 134 (53.8%) | 93 (50.8%) | 41 (62.1%) | ||
| >51 | 115 (46.2%) | 90 (49.2%) | 25 (37.9%) | ||
| Tumor position | 0.059 | 0.807 | |||
| Left | 139 (55.8%) | 103 (56.3%) | 36 (54.5%) | ||
| Right | 110 (44.2%) | 80 (43.7%) | 30 (45.5%) | ||
| BMI | 0.865 | 0.864 | |||
| <18.5 | 8 (3.2%) | 7 (3.8%) | 1 (1.5%) | ||
| ≥18.5 | 154 (61.8%) | 113 (61.7%) | 41 (62.1%) | ||
| ≥25 | 71 (28.5%) | 52 (28.4%) | 19 (28.8%) | ||
| ≥30 | 16 (6.4%) | 11 (6.0%) | 5 (7.6%) | ||
| Parturition | 2.166 | 0.537 | |||
| 0 | 33 (13.3%) | 26 (14.2%) | 7 (10.6%) | ||
| 1 | 150 (60.2%) | 110 (60.1%) | 40 (60.6%) | ||
| 2 | 54 (21.7%) | 36 (19.7%) | 18 (27.3%) | ||
| >2 | 12 (4.8%) | 11 (6.0%) | 1 (1.5%%) | ||
| cT stage | 4.379 | 0.201 | |||
| T1 | 22 (8.8%) | 17 (9.3%) | 5 (7.6%) | ||
| T2 | 187 (75.1%) | 141 (77.0%) | 46 (69.7%) | ||
| T3 | 35 (14.1%) | 23 (12.6%) | 12 (18.2%) | ||
| T4 | 5 (2.0%) | 2 (1.1%) | 3 (4.5%) | ||
| ER | 1.612 | 0.204 | |||
| Negative | 86 (34.5%) | 59 (32.2%) | 27 (40.9%) | ||
| Positive | 163 (65.5%) | 124 (67.8%) | 39 (59.1%) | ||
| PR | 0.613 | 0.434 | |||
| Negative | 118 (47.4%) | 84 (45.9%) | 34 (51.5%) | ||
| Positive | 131 (52.6%) | 99 (54.1%) | 32 (48.5%) | ||
| HER-2 | 4.019 | 0.045 | |||
| Negative | 161 (64.7%) | 125 (68.3%) | 36 (54.5%) | ||
| Positive | 88 (35.3%) | 58 (31.7%) | 30 (45.5%) | ||
| Ki-67 | 0.699 | 0.403 | |||
| ≤14% | 73 (29.3%) | 51 (27.9%) | 22 (33.3%) | ||
| >14% | 176 (70.7%) | 132 (72.1%) | 44 (66.7%) | ||
| Subtype | 5.369 | 0.252 | |||
| Luminal A | 25 (10.0%) | 20 (10.9%) | 5 (7.6%) | ||
| Luminal B/HER-2- | 100 (40.2%) | 77 (42.1%) | 23 (34.8%) | ||
| Luminal B/HER-2+ | 42 (16.9%) | 30 (16.4%) | 12 (18.2%) | ||
| TNBC | 36 (14.5%) | 28 (15.3%) | 8 (12.1%) | ||
| HER-2 enriched | 46 (18.5%) | 28 (15.3%) | 18 (27.3%) | ||
| P53 | 0.327 | 0.567 | |||
| Negative | 117 (47.0%) | 84 (45.9%) | 33 (50.0%) | ||
| Positive | 132 (53.0%) | 99 (54.1%) | 33 (50.0%) | ||
| pCR | 1.804 | 0.179 | |||
| No | 199 (79.9%) | 150 (82.0%) | 49 (74.2%) | ||
| Yes | 50 (20.1%) | 33 (18.0%) | 17 (25.8%) |
Abbreviation: BMI: body mass index; cT stage: clinical T stage; ER: estrogen receptor; PR: progesterone receptor; HER-2: human epidermal growth factor receptor-2; TNBC: triple negative breast cancer; pCR: pathologic complete response.